T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system-Reference-Cited by-同舟云学术

T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system

Published:2018-07-02 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Tamai Minori,Inukai Takeshi,Kojika Satoru,Abe Masako,Kagami Keiko,Harama Daisuke,Shinohara Tamao,Watanabe Atsushi,Oshiro Hiroko,Akahane Koshi,Goi Kumiko,Sugihara Eiji,Nakada Shinichiro,Sugita Kanji

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-27767-6.pdf

Reference50 articles.

1. Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nature reviews clinical oncology 14, 141–154 (2017).

2. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine 344, 1031–1037 (2001).

3. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2, 561–566 (1996).

4. Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396–4407 (2004).

5. Towatari, M. et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104, 3507–3512 (2004).

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance;Pharmacology Research & Perspectives;2024-06-21

2. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line;Cancer Science;2024-03-28

3. Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance;Annual Review of Pharmacology and Toxicology;2024-01-23

4. Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy;Cureus;2023-11-30

5. CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer;European Journal of Cell Biology;2023-06